Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors

BACKGROUND: The predictive power of novel biological markers for treatment response to immune checkpoint inhibitors (ICI) is still not satisfactory for the majority of patients with cancer. One should identify valid predictive markers in the peripheral blood, as this is easily available before and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jian-Guo, Donaubauer, Anna-Jasmina, Frey, Benjamin, Becker, Ina, Rutzner, Sandra, Eckstein, Markus, Sun, Roger, Ma, Hu, Schubert, Philipp, Schweizer, Claudia, Fietkau, Rainer, Deutsch, Eric, Gaipl, Udo, Hecht, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888377/
https://www.ncbi.nlm.nih.gov/pubmed/33593828
http://dx.doi.org/10.1136/jitc-2020-001845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888377/
https://www.ncbi.nlm.nih.gov/pubmed/33593828
http://dx.doi.org/10.1136/jitc-2020-001845

Ejemplares similares